Biomarker and imaging correlates of patients treated with tisagenlecleucel. (A) CRP trends of secondary CNS lymphoma patients treated with tisagenlecleucel. Red, D+30 responders; blue, D+30 nonresponders/deceased. (B) Time-matched serum and CSF (via ommaya) on days 0, 7, 14, and 28 of tisagenlecleucel infusion, as measured by Luminex assay for patient 3. Error bars, SEM. Data are technical triplicates. (C) MRI of patient 3 during inflammatory flare on D+6 with linear enhancement along the lower thoracic cord, conus, and cauda equina nerve roots (left panel, denoted by arrows) with subsequent resolution by D+180 (right panel). (D) MRI of patient 8 demonstrating resolution of the left middle cranial fossa enhancing mass lesion with decreased expansile T2/fluid-attenuated inversion recovery (FLAIR) hyperintensity in the left anterior temporal white matter.